Long-term safety of felzartamab for kidney transplant rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished the Week 52 visit in the main study (or are about to finish it).
- You received at least one dose of felzartamab in the main study, even if you later stopped treatment.
- If you are still getting felzartamab, your doctor thinks continuing is a good idea.
- You did not meet a rule that would have forced you to stop treatment in the main study (but kept going anyway).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called felzartamab to see if it can help people who have a type of kidney inflammation after a transplant, even without donor-specific antibodies. It might offer a new treatment option for those who are not getting better on their own.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This study tests a new medicine called mezagitamab for people whose kidney transplant is being rejected by their immune system (a condition called antibody-mediated rejection). The goal is to see if it can help stop the rejection and protect the transplanted kidney.
This is a long-term follow-up study for people who have already completed a study of the drug tegoprubart after a kidney transplant. It checks how safe and effective the drug is over a longer period.
This study tests whether felzartamab, given as an infusion, can help treat primary membranous nephropathy (a kidney disease causing protein in the urine and swelling). It may reduce protein loss and improve kidney function compared to standard care alone.
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
Hear when a new Antibody-mediated Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.